BTNL2 antibody
Contáctenos para saber el precio
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
BTNL2 antibody
category
Primary Antibodies
provider
FineTest
reference
FNab00985
tested applications
ELISA, WB
Description
Negative regulator of T-cell proliferation.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | butyrophilin-like 2 (BTNL2) |
| Host | Rabbit |
| Reactivity | Human, Mouse |
| Recommended Dilution | WB: 1:500-1:1000 |
| Clonality | polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Observed MW | 65 kDa |
| Purity | ≥95% as determined by SDS-PAGE |
| Purification | Immunogen affinity purified |
| Size 1 | 100µg |
| Form | liquid |
| Tested Applications | ELISA, WB |
| Storage | PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.) |
| UniProt ID | Q9UIR0 |
| Gene ID | 56244 |
| Alias | SS2,BTN7,BTL-II,HSBLMHC1,Butyrophilin-like protein 2 |
| Background | Antibody anti-BTNL2 |
| Status | RUO |
| Note | Mol. Weight 65 kDa |
Descripción
Butyrophilin like 2 (BTNL2) is an immunomodulatory protein expressed in epithelial and lymphoid tissues. BTNL2 interacts with T cells, modulating their activation and proliferation, thus playing a key role in maintaining immune homeostasis and preventing excessive immune responses. Genetic polymorphisms in BTNL2 are linked to susceptibility to autoimmune diseases, including sarcoidosis, rheumatoid arthritis, and Crohn's disease, as well as some cancers. Its expression in mucosal tissues suggests a role in regulating local immune responses to pathogens and maintaining the epithelial barrier. BTNL2's therapeutic potential is under investigation, particularly its ability to influence immune tolerance and suppress aberrant immune activation in inflammatory diseases and transplant rejection.
